MDT (Medtronic plc.): Themes, ETFs, and Basket Ideas
Last updated June 2026
Short answer
What does Medtronic plc. do?
Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Its business spans four main areas: Cardiovascular (pacemakers, defibrillators, heart valves, and cardiac ablation), Neuroscience (spine implants, neuromodulation for pain and movement disorders, and surgical navigation), Medical Surgical (surgical stapling, energy devices, and a growing robotic-surgery platform), and Diabetes (insulin pumps and continuous glucose monitoring). The company sells primarily to hospitals, surgeons, and health systems, generating durable, recurring demand tied to procedure volumes and chronic-disease management. Medtronic's scale gives it deep relationships with providers, a large installed base of devices, and the resources to fund extensive R&D and acquisitions. Growth depends on new product cycles, pipeline approvals, and global expansion, especially in emerging markets. Founded in 1949 and headquartered in Ireland for tax purposes (operationally rooted in Minnesota), Medtronic is a large-cap, dividend-growing medical-technology company tied to long-term healthcare demand and aging demographics.
Where is Medtronic plc. heading?
1. Diversified device portfolio.
Medtronic spans cardiovascular, neuroscience, medical surgical, and diabetes, so no single product or therapy dominates results. This breadth smooths revenue across product cycles and reimbursement changes, and the large installed base of implanted devices and capital equipment creates recurring demand for replacements, consumables, and follow-on procedures across health systems worldwide.
2. Innovation pipeline and new product cycles.
Growth is driven by new approvals and product cycles: pulsed-field ablation for atrial fibrillation, next-generation insulin pumps and continuous glucose monitoring, and the Hugo robotic-surgery system competing in soft-tissue robotics. A strong cadence of pipeline launches can reaccelerate growth in segments that had matured, and Medtronic's R&D scale supports a steady flow of new therapies.
3. Aging demographics and chronic disease.
Long-term demand for cardiac, spine, diabetes, and neurological therapies rises with aging populations and the growing prevalence of chronic disease. As a market leader, Medtronic is positioned to benefit from secular increases in procedure volumes, particularly as healthcare access expands in emerging markets.
4. Dividend growth and cash generation.
Medtronic is a Dividend Aristocrat with decades of consecutive increases, supported by steady cash flow from its diversified device base. This makes it a defensive, income-oriented holding within healthcare, with capital returned through dividends and buybacks alongside reinvestment and bolt-on acquisitions.
Risks worth tracking: Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. The Hugo robotic platform faces an entrenched Intuitive Surgical, and the diabetes business has battled competitive pressure and prior regulatory issues. Device companies face reimbursement pressure, hospital budget constraints, FDA approval and recall risk, and litigation exposure. A large international footprint brings currency headwinds. The valuation is moderate but the stock has lagged when growth disappointed. New-product execution, pipeline timing, and the ability to reaccelerate organic growth remain the key swing factors for the investment case.
Earnings and valuation (approximate, early 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Medtronic plc.'s investor relations page or your broker.
- Revenue (TTM): ~$33 billion
- Operating margin: ~20% (non-GAAP higher; GAAP affected by amortization)
- Net income (TTM): ~$4.5 billion
- EPS (TTM): ~$3.50 GAAP; non-GAAP higher
- P/E (TTM): ~17x on non-GAAP earnings
- Dividend yield: ~3.0%, a Dividend Aristocrat with decades of increases
- Free cash flow: ~$5 billion annually
- Segment mix: Cardiovascular largest, plus Neuroscience, Medical Surgical, and Diabetes
Medtronic trades at a moderate valuation relative to faster-growing medtech peers, reflecting its scale, diversification, and reliable dividend but also a track record of slower organic growth. The multiple has expanded when new product cycles reaccelerated growth and compressed during periods of execution stumbles. The yield gives it a defensive, income-oriented profile within healthcare.
MDT's competitors
Cardiovascular devices
Boston Scientific, Abbott, and Edwards Lifesciences compete in pacemakers, defibrillators, structural heart, and ablation. Pulsed-field ablation is a key battleground with Boston Scientific and Johnson & Johnson MedTech.
Surgical and robotics
Intuitive Surgical dominates soft-tissue robotic surgery, the market Medtronic's Hugo system targets. Johnson & Johnson, Stryker, and Becton Dickinson compete across surgical stapling, energy, and instruments.
Diabetes and neuroscience
Abbott (FreeStyle Libre), Dexcom, and Insulet compete in glucose monitoring and insulin delivery. Stryker, Globus Medical, and others compete in spine and neuromodulation.
Using MDT in a Walnut basket
The most useful question to ask about a single stock is rarely “will it go up?”. It's “does this fit a thesis I actually believe in, and how do I size it alongside other stocks that fit the same thesis?” That's what Walnut is built for.
Open the AI assistant on Walnut and describe a thesis (for example: “the AI infrastructure buildout”, “dividend growth large-caps”, “global semiconductors”) where MDT would naturally fit. The AI proposes 5 to 6 constituents with target weights, you review, and you can fund the basket through your broker once you're ready.
Build a basket around MDT with Walnut
Use Medtronic plc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is Medtronic's ticker symbol?
+
MDT, listed on the New York Stock Exchange. Officially Medtronic plc. Founded in 1949, operationally rooted in Minnesota with legal domicile in Ireland. Trades during US market hours and is available at every major US brokerage.
What does Medtronic do?
+
Medtronic is one of the world's largest medical device companies. It makes therapies and devices across cardiovascular (pacemakers, defibrillators, heart valves, ablation), neuroscience (spine, neuromodulation), medical surgical (stapling, energy, robotic surgery), and diabetes (insulin pumps, glucose monitoring), selling mainly to hospitals and surgeons.
Who are Medtronic's main competitors?
+
Boston Scientific, Abbott, and Edwards Lifesciences in cardiovascular; Intuitive Surgical, Johnson & Johnson, and Stryker in surgical and robotics; Abbott, Dexcom, and Insulet in diabetes. Medtronic competes on scale and breadth across these therapy areas.
Does Medtronic pay a dividend?
+
Yes. Medtronic is a Dividend Aristocrat with decades of consecutive annual increases, yielding roughly 3.0% as of early 2026. Steady cash flow from its diversified device portfolio supports the dividend alongside buybacks and reinvestment, giving it a defensive, income-oriented profile within healthcare.
Is Medtronic a good dividend stock?
+
Descriptive, not a recommendation. Medtronic is a Dividend Aristocrat yielding around 3.0% with a multi-decade increase streak and reliable cash flow. The income profile is durable, though organic growth has at times been slow, which is a consideration for total return. Whether it suits an income strategy depends on individual goals. Walnut is informational, not investment advice.
What is Medtronic's P/E ratio?
+
Approximately 17x on non-GAAP earnings as of early 2026, a moderate valuation relative to faster-growing medtech peers. GAAP P/E is higher because of acquisition-related amortization. The multiple has expanded when new product cycles reaccelerated growth and compressed during execution stumbles.
Is Medtronic in the S&P 500?
+
Yes. MDT is a long-standing S&P 500 constituent and a major healthcare holding by market cap. It is widely held across passive index funds, healthcare ETFs, and dividend-growth strategies.
Which ETFs hold Medtronic?
+
MDT appears in broad market funds like VOO and VTI, healthcare-sector ETFs such as XLV and VHT, medical-device thematic funds, and many dividend-focused funds including those screening for Dividend Aristocrats.
Is Medtronic a growth or value stock?
+
Medtronic leans toward the value and dividend side of medtech. It is a large, mature, diversified device company with a strong yield and moderate valuation, rather than a high-growth name. Reacceleration depends on new product cycles like pulsed-field ablation, next-gen diabetes products, and the Hugo robotic platform.
What sector is Medtronic in?
+
Healthcare under GICS classification, within the health care equipment and supplies industry. Medtronic is grouped with other medical device makers, reflecting its therapy and device portfolio sold to hospitals and surgeons.
What is Medtronic's Hugo robot?
+
Hugo is Medtronic's robotic-assisted surgery system, designed to compete in soft-tissue procedures against Intuitive Surgical's dominant da Vinci platform. It is one of several new product cycles, alongside pulsed-field ablation and diabetes devices, that investors watch as potential growth drivers.
Which thematic baskets typically include Medtronic?
+
On Walnut, MDT commonly appears in healthcare and medical-device baskets, defensive dividend-growth baskets given its Aristocrat status, and aging-demographics baskets tied to long-term chronic-disease and procedure demand.
Is Medtronic a good stock to buy?
+
Descriptive, not a recommendation. Medtronic offers a diversified device portfolio, a multi-decade dividend-growth record, exposure to aging-demographics demand, and a pipeline of new product cycles. Counterpoints include historically slow organic growth, competition from nimbler peers, reimbursement and regulatory risk, and currency exposure. Whether it fits a portfolio depends on individual goals and risk tolerance. Walnut is informational, not investment advice.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Medtronic plc.'s investor relations page or your broker before making investment decisions.